Report ID: SQSG30B2035
Report ID:
SQSG30B2035 |
Region:
Global |
Published Date: February, 2024
Pages:
260
|
Tables:
118 |
Figures:
77
General Anesthesia Drugs Market Driver
In recent decades, cancer has become much more common in the United States. The National Cancer Institute estimates that there are 16.9 million cancer survivors in the United States. The number of cancer survivors is expected to reach 22.2 million by 2030. The most common cancers are lung and bronchus cancer, breast cancer, prostate cancer, melanoma of the skin, colon and rectum cancer, bladder cancer, non-Hodgkin lymphoma, endometrial cancer, leukemia, kidney and renal pelvic cancer, pancreatic cancer, thyroid cancer, and liver cancer (listed in descending order based on estimated new cases in 2020). Prostate, lung, and colorectal cancers will account for 43% of all cancers diagnosed in men by 2020. Breast, lung, and colorectal cancer, on the other hand, accounted for more than half of all new malignancies diagnosed in women in 2020. Because cancer surgery offers the best chance of curing many tumors, particularly if the cancer is contained, the increased prevalence of cancer will result in an increase in the number of procedures. Because general anaesthesia is frequently used for surgical operations to treat cancer, the US general anaesthesia market will grow as the prevalence of cancer rises.
General Anesthesia Drugs Market Restraint
The use of pharmacologic agents, particularly general anaesthetic medicines, in paediatric patients necessitates extra caution. Infants and young children respond differently to anaesthetic medicines than adults due to a variety of characteristics such as body composition, protein binding, body temperature, cardiac output distribution, and functional maturity of the liver and kidneys. Various investigations have found that using general anaesthetics and sedative medicines in pregnant and young animals for more than 3 hours caused extensive nerve cell death in the brain. Recent human research indicates that a single, brief exposure to general anaesthetics and sedative medicines in new-borns or toddlers is unlikely to have a harmful impact on behaviour or learning. Considering this, the US Food and Drug Administration issued additional cautions about the use of general anaesthetics and sedative medicines in young children and pregnant women. Patients requiring surgery or other unpleasant and stressful treatments, including small children and pregnant women, require general anaesthetics and sedative medicines. The US Food and Drug Administration has issued a warning concerning the repeated or prolonged use of general anaesthetics and sedative medicines during operations or procedures in children under the age of three and pregnant women. The possible danger connected with the use of general anaesthetic medications in young children and pregnant women may cause a decline in the adoption of general anaesthetics by healthcare providers, stifling market growth.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQSG30B2035